• 1
    Whitby D, Howard MR, Tenant-Flowers M et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet 1995; 346: 799802.
  • 2
    Engels EA, Biggar RJ, Marshall VA et al. Detection and quantification of Kaposi’s sarcoma-associated herpesvirus to predict AIDS-associated Kaposi’s sarcoma. AIDS 2003; 17: 18471851.
  • 3
    Min J, Katzenstein DA. Detection of Kaposi’s sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi’s sarcoma, CD4 cell count, and HIV RNA levels. AIDS Res Hum Retroviruses 1999; 15 (1): 5155.
  • 4
    Tedeschi R, Enbom M, Bidoli E, Linde A, De PP, Dillner J. Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi’s sarcoma. J Clin Microbiol 2001; 39: 42694273.
  • 5
    Brown EE, Whitby D, Vitale F et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. Cancer 2006; 107: 22822290.
  • 6
    Vitale F, Briffa DV, Whitby D et al. Kaposi’s sarcoma herpes virus and Kaposi’s sarcoma in the elderly populations of 3 Mediterranean islands. Int J Cancer 2001; 91: 588591.
  • 7
    Miller G, Heston L, Grogan E et al. Selective switch between latency and lytic replication of Kaposi’s sarcoma herpesvirus and Epstein–Barr virus in dually infected body cavity lymphoma cells. J Virol 1997; 71: 314324.
  • 8
    Hu J, Garber AC, Renne R. The latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. J Virol 2002; 76: 1167711687.
  • 9
    Parravicini C, Chandran B, Corbellino M et al. Differential viral protein expression in Kaposi’s sarcoma-associated herpesvirus-infected diseases: Kaposi’s sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. Am J Pathol 2000; 156: 743749.
  • 10
    Dupin N, Fisher C, Kellam P et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 1999; 96: 45464551.
  • 11
    Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 2010; 120: 939949.
  • 12
    Bihl F, Mosam A, Henry LN, Chisholm JV 3rd et al. Kaposi’s sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi’s sarcoma. AIDS 2007; 21: 12451252.
  • 13
    Bihl F, Berger C, Chisholm JV 3rd et al. Cellular immune responses and disease control in acute AIDS-associated Kaposi’s sarcoma. AIDS 2009; 23: 19181922.
  • 14
    Guihot A, Dupin N, Marcelin AG et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis 2006; 194: 10781088.
  • 15
    Barozzi P, Bonini C, Potenza L et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation 2008; 86: 738744.
  • 16
    Barozzi P, Potenza L, Riva G et al. Changes in T-cell responses against human herpesvirus-8 correlate with the disease course of iatrogenic Kaposi’s sarcoma in a patient with undifferentiated arthritis. Semin Arthritis Rheum 2009; 39: 170175.
  • 17
    Franceschi S, Maso LD, Rickenbach M et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99: 800804.
  • 18
    Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi’s sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi’s sarcoma. J Clin Oncol 2004; 22: 399402.
  • 19
    Wilkinson J, Cope A, Gill J et al. Identification of Kaposi’s sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002; 76: 26342640.
  • 20
    Flores R, Goedert JJ. Reconstitution of immune responses against Kaposi sarcoma-associated herpesvirus. AIDS 2010; 24: 22792281.
  • 21
    Valenti RM, Amodio E, Nam JM et al. Delayed-type hypersensitivity in classic Kaposi sarcoma patients and controls. Br J Cancer 2011; 104: 433436.
  • 22
    Anderson LA, Lauria C, Romano N et al. Risk factors for classical Kaposi sarcoma in a population-based case-control study in Sicily. Cancer Epidemiol Biomarkers Prev 2008; 17: 34353443.
  • 23
    Sokal JE. Editorial: measurement of delayed skin-test responses. N Engl J Med 1975; 293: 501502.
  • 24
    Barcy S, De Rosa SC, Vieira J et al. Gamma delta + T cells involvement in viral immune control of chronic human herpesvirus 8 infection. J Immunol 2008; 180: 34173425.
  • 25
    Della Bella S, Taddeo A, Colombo E et al. Human herpesvirus-8 infection leads to expansion of the preimmune/natural effector B cell compartment. PLoS One 2010; 5: e15029.
  • 26
    Luppi M, Trovato R, Barozzi P et al. Suppressive effect of human herpesvirus-8/Kaposi sarcoma-associated herpesvirus on in vitro colony formation of hematopoietic progenitor cells. Leuk Res 2005; 29: 951953.
  • 27
    Sullivan SG, Hirsch HH, Franceschi S et al. Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study. AIDS 2010; 24: 22452252.
  • 28
    Lambert M, Gannagé M, Karras A et al. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood 2006; 108: 38713880.
  • 29
    Mesri EA, Cesarman E, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10: 707719.
  • 30
    Bourboulia D, Aldam D, Lagos D et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 2004; 18: 485493.